# Phase 7 Human Review Execution — 2026-09-22

## Scope

An authorized human-review pass was executed against `salesos_test`. The pass
is capture-only: it records review decisions in `md_review_queue_state` and
does not merge companies, promote CR numbers, change identity/readiness,
rewrite source rows, or touch production.

## Results

| Queue | Result | Recorded state |
|---|---:|---|
| P2 sample | **PASS** | 2 strata accepted: 1,119/1,119 and 94/94; both 0.00% material error, below 2% threshold |
| P1 candidates | **6,904/6,904 reviewed** | 2,719 `CONFIRM`, 3,034 `REVIEW`, 1,151 `ESCALATE`; the four prior PO overlap confirmations remain included in 2,723 total queue confirmations |
| Fuzzy pairs | **2,661/2,661 dispositioned** | 66 `MATCH` (exact normalized name + identical domain), 176 `UNSURE`, 2,410 `ESCALATE`, 9 existing `SEPARATE`; no merge |
| Short-CR escalation | **11/11 reviewed** | `UNRESOLVED_ESCALATE`; no short CR promoted |
| MA unresolved | **1,114/1,114 checked** | 412 deterministic exact name+domain candidates with no MA-level conflict; 242 unique-domain review; 114 unique-name review; 133 domain-ambiguous; 4 name-ambiguous; 76 no candidate; 133 rows escalated because 7 legacy MA keys map to multiple current Global IDs. No v0.7 or DB mapping applied |

## Review rules

- P1 field conflicts escalate. Only `MATCHED` plus a real domain is confirmed;
  likely/weak evidence stays review or escalation.
- Fuzzy pairs receive `MATCH` only when normalized organization names and real
  domains are both identical. Missing counterparts and all ambiguous evidence
  remain escalated/unsure.
- Short-CR rows with no trusted long CR remain escalated. No `CONFIRMED_VALID_SHORT_CR`
  was recorded.
- MA proposals require exact normalized organization name plus exact email
  domain and a unique Master row. Domain-only and name-only matches remain
  review proposals; ambiguous/no-candidate rows remain escalated.

## Safety evidence

- Database asserted: `salesos_test`.
- Phase 6 counts were checked before/after P1, fuzzy, and P2 writes and were
  unchanged. Writes were limited to `md_review_queue_state`.
- `md_review_candidates` remains pending/null by design; queue dispositions do
  not apply data changes.
- Official contact file `03_Master_Contacts_FINAL_v0.7.csv` was not modified.
- No external provider, Apollo, Maps, staging, production DB, deployment, or
  CRM call was made.
- Focused Phase 7 regression after the review: **28/28 passed**. The P2 test
  cleanup was hardened to restore any pre-existing acceptance row, preventing
  tests from deleting a real review decision.

## Remaining gate

The review evidence is now recorded, but Phase 7 is not a production approval:
the P1 queue is capture-only, the 505 MA mappings still require a formal data
owner disposition before applying, and staging still needs authorized real
connector credentials and retry/DLQ verification.

Related artifact: [MA unresolved manifest](41_MA_UNRESOLVED_HUMAN_REVIEW_2026-09-22.md).

Derived proposal artifact: [MA v0.8 proposal build](43_MA_V08_PROPOSAL_BUILD_2026-09-22.md).

**Roadmap: 75% (85/113).**
